Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2025-04-09 00:00:00 ET · period of report 2025-04-09 · accession 0001628280-25-017223 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-09 | 2025-04-09 | NAGE | Fried Robert N | CEO, Dir | M - OptEx | $3.30 | +66.7K | 1.04M | +7% | +$220.0K |
| D | 2025-04-09 | 2025-04-09 | NAGE | Fried Robert N | CEO, Dir | M - OptEx | $0.00 | -66.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-09 | M | A | 66,667 | $3.30 | 1,038,981 | D | — | — | |
| 2 | Derivative | Stock Options (right to buy) | 2025-04-09 | M | D | 66,667 | $0.00 | 0 | D | $3.30 · 2015-08-30 to 2025-07-29 | 66,667 Common Stock |